[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369638-105":59,"doc-detail-369638-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumor-infiltrating-lymphocytes-in-breast-and-female-genital-tract-cancers-overlooked-potential-and-unexplored-frontiers","Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers - Overlooked Potential and Unexplored Frontiers","","The manuscript reviews the prognostic relevance of tumor-infiltrating lymphocytes (TILs) in breast and lower female genital tract cancers, addressing why outcomes remain poor despite advances in cancer immunotherapy. It synthesizes evidence linking TIL counts and density, immune-cell subtype combinations, and immunotherapy approaches to patient endpoints across multiple cancer types. Findings show generally favorable associations with high TIL infiltration, while breast DCIS can show worse prognosis, with tumor microenvironment, ethnicity, and molecular profiles complicating interpretation. The work highlights TIL-based personalized immunotherapy potential, especially for recurrent, refractory ovarian cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-infiltrating-lymphocytes-in-breast-and-female-genital-tract-cancers-overlooked-potential-and-unexplored-frontiers/369638/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-infiltrating-lymphocytes-in-breast-and-female-genital-tract-cancers-overlooked-potential-and-unexplored-frontiers/369638.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do tumor-infiltrating lymphocytes (TILs) relate to cancer immunotherapy outcomes?","Question",{"text":112,"@type":113},"The review explains that growing success in cancer immunotherapies has improved oncology, but mortality remains high for common breast and lower female genital tract cancers. TILs provide prognostic and therapeutic relevance by reflecting anti-tumor immune activity in the tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What prognostic pattern is generally observed with high TIL infiltration?",{"text":117,"@type":113},"High TIL infiltration, especially CD8+ T-cells, generally correlates with improved outcomes in endometrial cancer (notably the POLE-ultramutated subgroup), invasive breast cancer, and ovarian epithelial tumors. However, in breast ductal carcinoma in situ (DCIS), elevated TIL counts are linked to a worse prognosis.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is TIL prognostic usefulness considered complicated?",{"text":121,"@type":113},"The manuscript notes that ethnicity, the tumor microenvironment (TME), and molecular profiles can complicate how TILs should be interpreted clinically. It also highlights immune evasion mechanisms that render TILs dysfunctional.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369638,1790215794,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Cancer Medicine  \n| \u003Cbr> REVIEW  OPEN ACCESS \u003Cbr>Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers: Overlooked Potential and Unexplored Frontiers\u003Cbr>Kristijan Skok1,2  | Umberto Maccio3 | Spencer D. Martin4 | Konstantin Bräutigam5\u003Cbr>1Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria | 2Institute of Biomedical Sciences, Faculty of\u003Cbr>Medicine, University of Maribor, Maribor, Slovenia | 3Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland | 4Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada | 5Centre for\u003Cbr>Evolution and Cancer, Institute of Cancer Research, London, UK Correspondence: Kristijan Skok ([kristijan.skok@medunigraz.at](kristijan.skok@medunigraz.at))\u003Cbr>Received: 6 March 2025 | Revised: 23 June 2025 | Accepted: 24 June 2025\u003Cbr>Funding: KB was funded by the Swiss National Science Foundation (P500PM_ 217647/1). KS was funded by Javna Agencija za Raziskovalno in Inovacijsko Dejavnost RS (P3-0036, I0-0029) .\u003Cbr>Keywords: breast cancer | endometrial cancer | fallopian tube | immunotherapy | ovarian cancer | review | tumor microenvironment (TME) | tumorinfiltrating lymphocytes (TILs) | vulvar cancer |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>Background: The growing success of cancer immunotherapies has led to significant advances in oncology. However, despite these promising developments, cancer-related mortality remains high for common cancer types such as breast and lower female genital tract cancers.\u003Cbr>Method: Here, we synthesize recent findings on the prognostic relevance of tumor-infiltrating lymphocytes (TILs) in breast, endometrial, tubo-ovarian, and vulvar cancer. Our analysis covers the relationship between TIL counts and density, immune cell subtype combinations, immunotherapy approaches, and patient outcomes.\u003Cbr>Results: High TIL infiltration, especially CD8+ T-cells, generally correlates with improved outcomes such as in endometrial cancer (especially the POLE-ultramutated subgroup), invasive breast cancer, and ovarian epithelial tumors. However, in ductal carcinoma in situ (DCIS) of the breast, elevated TIL counts are linked to a worse prognosis. Ethnicity, the tumor microenvironment (TME), and molecular profiles further complicate the prognostic utility of TILs.\u003Cbr>Conclusions: TIL-based therapies have shown potential in personalized immunotherapy, particularly in recurrent, refractory ovarian cancer. Limited research on rarer gynecologic tumors hinders broader clinical applications. |  |\n| 1 | Introduction | gynecologist, or oncologist [1] . While the role of TILs in breast |\n| Tumor-infiltrating lymphocytes (TILs) have become a hot topic in daily clinical routine, be it the routine of a pathologist, | cancer (BC) has been investigated for years [2], their significance in cervical, endometrial, tubo-ovarian, and vulvo-vaginal cancers is less explored. |\n| Kristijan Skok and Umberto Maccio joint first authorship. |  |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |  |\n\nCancer Medicine, 2025; 14:e71023 1 of 15  \n[https://doi.org/10.1002/cam4.71023](https://doi.org/10.1002/cam4.71023)  \nFIGURE 1 | Multi-step mechanism of tumor-infiltrating lymphocytes (TILs) . (A) Migration: TILs migrate via the bloodstream to reach tumor sites, guided by cytokines (blue dots) and adhesion molecules (green) . (B) Tumor recognition: On site, TILs invade the collagen matrix (light blue) of the tumor microenvironment (TME) and are confronted with a more or less hostile local cell infiltrate, e.g., cells of the innate immunity such as (tumor-associated) macrophages (TAMs), tumor-infiltrating neutrophils (TINs), and dendritic cells. TA","cbCaihiW0g8b0cvX","https://ap.wps.com/l/cbCaihiW0g8b0cvX","pdf",1428497,15,"English","# ABSTRACT\n## Background, Method, Results, Conclusions\n# Introduction\n## TILs and the Tumor Microenvironment\n## Immune-cell interactions in the TME","[{\"question\":\"How do tumor-infiltrating lymphocytes (TILs) relate to cancer immunotherapy outcomes?\",\"answer\":\"The review explains that growing success in cancer immunotherapies has improved oncology, but mortality remains high for common breast and lower female genital tract cancers. TILs provide prognostic and therapeutic relevance by reflecting anti-tumor immune activity in the tumor microenvironment.\"},{\"question\":\"What prognostic pattern is generally observed with high TIL infiltration?\",\"answer\":\"High TIL infiltration, especially CD8+ T-cells, generally correlates with improved outcomes in endometrial cancer (notably the POLE-ultramutated subgroup), invasive breast cancer, and ovarian epithelial tumors. However, in breast ductal carcinoma in situ (DCIS), elevated TIL counts are linked to a worse prognosis.\"},{\"question\":\"Why is TIL prognostic usefulness considered complicated?\",\"answer\":\"The manuscript notes that ethnicity, the tumor microenvironment (TME), and molecular profiles can complicate how TILs should be interpreted clinically. It also highlights immune evasion mechanisms that render TILs dysfunctional.\"}]","Tumor-Infiltrating Lymphocytes in Breast and Female Genital Tract Cancers - Overlooked Potential and Unexplored Frontiers | PDF",1790183795,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38c7dab7c2ea020c421cecea34a51fba.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddec072b0b85854a15682157b587b09a.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7662054058e418a22ef553af0e2ec4d6.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdf725d6899fea2156e1fcd266fe65f8.webp",980,1287]